Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update
August 10, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®
August 09, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today...
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
May 27, 2021 08:15 ET
|
Alimera Sciences, Inc.
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
May 17, 2021 08:12 ET
|
Alimera Sciences, Inc.
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced...
Alimera Sciences Announces First Quarter 2021 Financial Results
April 28, 2021 16:32 ET
|
Alimera Sciences, Inc.
ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update
April 22, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, April 22, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Receives $20 Million From Ocumension Therapeutics
April 14, 2021 09:00 ET
|
Alimera Sciences, Inc.
Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone paymentsOcumension makes a $10 million equity investment in...
Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021
April 09, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference
March 18, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, March 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland
March 17, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, March 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...